TrialCancer medicine2024

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial.

Qinglian Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.